Connective tissue growth factor-2

Details Connective tissue growth factor-2 Connective tissue growth factor-2

1999-07-08

2003-03-18

McGarry, Sean (Department: 1635)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

C435S006120, C435S455000, C435S069100, C435S069700, C530S300000

Reexamination Certificate

active

06534630

ABSTRACT:

This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptide of the present invention is connective tissue growth factor-2 sometimes hereinafter referred to as “CTGF-2”. The invention also relates to inhibiting the action of such polypeptides.
The CTGF polypeptides are structurally and functionally related to a family of growth factors which include IGF (insulin-like growth factor), PDGF (platelet-derived growth factor), and FGF (fibroblast growth factor). This emerging family of secreted proteins are a group of cysteine-rich proteins. This group of growth factors are important for normal growth, differentiation, morphogenesis of the cartilaginous skeleton of an embryo and cell growth. Among some of the functions that have been discovered for these growth factors are wound healing, tissue repair, implant fixation and stimulating increased bone mass.
The extended superfamily of growth factors include TGF (transforming growth factor), bone morphogenic factors, and activins, among others.
The most well-known growth factor, TGF exerts a number of different effects on a variety of cells. For example, TGF-&bgr; can inhibit the differentiation of certain cells of mesodermal origin (Florini, J. R. et al.,
J. Biol. Chem.,
261:1659-16513 (1986) induced the differentiation of others (Seyedine, S. M. et al.,
PNAS USA,
82:2267-2271 (1987) and potently inhibit proliferation of various types of epithelial cells, (Tucker, R. F.,
Science,
226:705-705 (1984)). This last activity has led to the speculation that one important physiological role for TGF-&bgr; is to maintain the repressed growth state of many types of cells. Accordingly, cells that lose the ability to respond to TGF-&bgr; are more likely to exhibit uncontrolled growth and become tumorigenic.
Accordingly, due to amino acid sequence homology the polypeptide of the present invention is a member of this extended family of growth factors which has many effects on a variety of different tissues.
In accordance with one aspect of the present invention, there is provided a novel mature polypeptide, as well as biologically active and diagnostically or therapeutically useful fragments, analogs and derivatives thereof. The polypeptide of the present invention is of human origin.
In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules encoding a polypeptide of the present invention including mRNAs, DNAS, cDNAs, genomic DNAs as well as analogs and biologically active and diagnostically or therapeutically useful fragments thereof.
In accordance with yet a further aspect of the present invention, there is provided a process for producing such polypeptide by recombinant techniques comprising culturing recombinant prokaryotic and/or eukaryotic host cells, containing a nucleic acid sequence encoding a polypeptide of the present invention, under conditions promoting expression of said protein and subsequent recovery of said protein.
In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such polypeptide, or polynucleotide encoding such polypeptide for therapeutic purposes, for example, enhancing the repair of connective and support tissue, promoting the attachment, fixation and stabilization of tissue implants and enhancing wound healing.
In accordance with yet a further aspect of the present invention, there are provided antibodies against such polypeptides.
In accordance with yet a further aspect of the present invention, there is also provided nucleic acid probes comprising nucleic acid molecules of sufficient length to specifically hybridize to a nucleic acid sequence of the present invention.
In accordance with yet a further aspect of the present invention, there are provided antibodies against such polypeptides.
In accordance with another aspect of the present invention, there are provided agonists which mimic the polypeptide of the present invention and binds to the receptors.
In accordance with yet another aspect of the present invention, there are provided antagonists to such polypeptides, which may be used to inhibit the action of such polypeptides, for example, in the treatment of CTGF dependent tumor growth.
In accordance with still another aspect of the present invention, there are provided diagnostic assays for detecting diseases or susceptibility to diseases related to mutations in the nucleic acid sequences encoding a polypeptide of the present invention.
In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such polypeptides, or polynucleotides encoding such polypeptides, for in vitro purposes related to scientific research, for example, synthesis of DNA and manufacture of DNA vectors.
These and other aspects of the present invention should be apparent to those skilled in the art from the teachings herein.


REFERENCES:
patent: 5408040 (1995-04-01), Grotendorst et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5837258 (1998-11-01), Grotendorst
patent: 5944710 (1999-08-01), Dev et al.
patent: 6051424 (2000-04-01), Kato et al.
patent: 0495674 (1992-07-01), None
patent: 495 674 (1992-07-01), None
patent: WO 88/03409 (1988-05-01), None
patent: WO 89/08667 (1989-09-01), None
patent: WO 94/03599 (1994-02-01), None
patent: WO 97/33995 (1997-09-01), None
patent: WO 00/35939 (2000-06-01), None
Timothy P. O'Brien et al., Expression of cyr61, a Growth Factor-Inducible Immediate-Early Gene; Molecular and Cellular Biology, Jul. 1990, pp. 3569-3577.*
Branko V. Latinkic et al., Promoter function and structure of the growth factor-inducible immediate early gene cyr61; Nucleic Acids Research, 1991, vol. 19, No. 12 pp. 3261-3267.*
U.S. patent application No. 09/912,293, Rosen et al., file not published.
Geneseq Accession No. AAT97142, Toyobo, K.K., “Human monocyte mature differentiation factor encoding cDNA” (Mar. 5, 1998).
Geneseq Accession No. AAW35957, Toyobo, K.K., “a monocyte mature differentiation factor—useful for the long term tissue culture of macrophase(s)” (Mar. 5, 1998).
Geneseq Accession No. AAT94699, Lau, L.F., “Human cysteine rich protein 61 (Cyr61)cDNA” (Mar. 27, 1998).
Geneseq Accession No. AAW35730, Lau, L.F., “Human cysteine rich protein 61 (Cyr61)” (Mar. 27, 1998).
International Search Report for PCT/US01/21799.
Latinkic et al.,Nucleic Acids Research, 19(12):3261-3267 (1991).
O'Brien et al.,Molecular and Cellular Biology, 10(7):3569-3577 (1990).
Simmons et al.,Proc. Natl. Acad. Sci. USA, 86:1178-1182 (1989).
Oemar et al.,Hyertension, 22(3):424 (1993).
Oemar et al.,European Heart Journal, 15(Abstr. Suppl.):486 (1994).
Bradham et al.,Journal of Cell Biology, 114(6):1285-1294 (1991).
George et al., “Current methods in sequence comparison and analysis,” inMacromolecular Sequencing and Synthesis, Selected Methods and Applications, D.H. Schlesinger (ed.), Alan R. Liss, Inc., New York, NY, pp. 127-149 (1988).
Boswell et al., “Sequence Comparison and alignment: the measurement and interpretation of sequence similarity,” inComputational Molecular Biology: Sources and Methods for Sequence Analysis, Arthur M. Lesk (ed.), Oxford University Press, New York, NY, pp. 161-178 (1988).
O'Brien et al., “Expression of the growth factor-inducible immediate early gene cyr61 correlates with chondrogenesis during mouse embryonic development,” inCell Growth Differ., 3(9):645-654 (Sep. 1992).
GeneSeq Accession No. Q26421 (Jan. 18, 1993).
GeneSeq Accession No. Q26422 (Jan. 18, 1993).
GeneSeq Accession No. R25565 (Jan. 18, 1993).
GeneSeq Accession No. R25566 (Jan. 18, 1993).
GeneSeq Accession No. R46078 (Oct. 19, 1994).
GeneSeq Accession No. Q57417 (Oct. 19, 1994).

Affiliated with

Also associated with

Rating

Connective tissue growth factor-2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Connective tissue growth factor-2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Connective tissue growth factor-2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3078869